OrbiMed’s Natera NTRA Stock Holding History

OrbiMed’s Portfolio NTRA Stock Details NTRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71.1M	Hold	262,000	–	–	1.32%	20
2026 Q1	$52.4M	Sell	262,000 -103,800	-28%	-$22.3M	1.04%	30
2025 Q4	$83.8M	Sell	365,800 -63,500	-15%	-$13.2M	1.71%	18
2025 Q3	$69.1M	Sell	429,300 -164,134	-28%	-$26M	1.62%	19
2025 Q2	$100M	Buy	593,434 +46,434	+8%	+$7.24M	2.5%	13
2025 Q1	$77.4M	Buy	547,000 +134,000	+32%	+$21.5M	1.84%	17
2024 Q4	$65.4M	Sell	413,000 -274,500	-40%	-$40M	1.34%	25
2024 Q3	$87.3M	Hold	687,500	–	–	1.59%	19
2024 Q2	$74.4M	Sell	687,500 -211,931	-24%	-$21.5M	1.47%	19
2024 Q1	$82.3M	Sell	899,431 -55,050	-6%	-$4.14M	1.51%	23
2023 Q4	$59.8M	Buy	954,481 +33,900	+4%	+$1.69M	1.19%	30
2023 Q3	$40.7M	Sell	920,581 -53,000	-5%	-$2.7M	0.87%	41
2023 Q2	$47.4M	Hold	973,581	–	–	0.86%	43
2023 Q1	$54.1M	Sell	973,581 -972,772	-50%	-$46.7M	1.06%	31
2022 Q4	$78.2M	Buy	1,946,353 +441,200	+29%	+$18.2M	1.5%	21
2022 Q3	$66M	Sell	1,505,153 -156,200	-9%	-$7.44M	1.22%	28
2022 Q2	$58.9M	Buy	1,661,353 +65,968	+4%	+$2.44M	1.07%	31
2022 Q1	$64.9M	Buy	1,595,385 +181,400	+13%	+$10.9M	1.05%	33
2021 Q4	$132M	Sell	1,413,985 -158,815	-10%	-$16.5M	1.7%	18
2021 Q3	$175M	Sell	1,572,800 -485,000	-24%	-$55.6M	1.93%	12
2021 Q2	$234M	Sell	2,057,800 -138,100	-6%	-$14.1M	2.36%	11
2021 Q1	$223M	Buy	2,195,900 +85,200	+4%	+$9.34M	2.08%	14
2020 Q4	$210M	Hold	2,110,700	–	–	1.84%	14
2020 Q3	$152M	Sell	2,110,700 -1,129,814	-35%	-$64.2M	1.92%	15
2020 Q2	$162M	Sell	3,240,514 -106,486	-3%	-$4.27M	2.27%	14
2020 Q1	$99.9M	Buy	3,347,000 +906,387	+37%	+$30.3M	1.68%	21
2019 Q4	$82.2M	Sell	2,440,613 -559,515	-19%	-$20.6M	1.17%	31
2019 Q3	$98.4M	Sell	3,000,128 -224,200	-7%	-$6.63M	1.87%	16
2019 Q2	$88.9M	Buy	3,224,328 +2,146,742	+199%	+$47.4M	1.38%	21
2019 Q1	$22.2M	Buy	1,077,586 +393,500	+58%	+$6.16M	0.34%	69
2018 Q4	$9.55M	Hold	684,086	–	–	0.18%	86
2018 Q3	$16.4M	Sell	684,086 -300,000	-30%	-$7.25M	0.2%	95
2018 Q2	$18.5M	Sell	984,086 -592,104	-38%	-$7.2M	0.22%	97
2018 Q1	$14.6M	Hold	1,576,190	–	–	0.18%	91
2017 Q4	$14.2M	Hold	1,576,190	–	–	0.18%	90
2017 Q3	$20.3M	Buy	1,576,190 +300,000	+24%	+$3.33M	0.19%	84
2017 Q2	$13.9M	Hold	1,276,190	–	–	0.15%	91
2017 Q1	$11.3M	Hold	1,276,190	–	–	0.13%	91
2016 Q4	$14.9M	Hold	1,276,190	–	–	0.19%	75
2016 Q3	$14.2M	Hold	1,276,190	–	–	0.16%	87
2016 Q2	$15.4M	Hold	1,276,190	–	–	0.16%	82
2016 Q1	$12.1M	Hold	1,276,190	–	–	0.13%	82
2015 Q4	$13.8M	Hold	1,276,190	–	–	0.12%	81
2015 Q3	$13.8M	Buy	+1,276,190	New	+$21.6M	0.14%	81

Other funds holding NTRA

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's NTRA Position: Q2 2026 in Review

OrbiMed held its Natera (NTRA) position steady in Q2 2026 at 262,000 shares worth $71.1M. The position accounts for 1.32% of the portfolio, ranked #20.

OrbiMed first reported a position in NTRA in Q3 2015 and has held it in 44 quarters since. The position peaked at $234M in Q2 2021. 846 funds tracked by Wall St. Rank hold NTRA as of Q2 2026.

OrbiMed held 262,000 shares of Natera worth $71.1M as of Q2 2026.
OrbiMed left its Natera share count unchanged in Q2 2026.
Natera made up 1.32% of OrbiMed's portfolio in Q2 2026, its #20 holding.
OrbiMed first reported a position in Natera in Q3 2015 and has held it in 44 quarters since.
OrbiMed's Natera position peaked at $234M in Q2 2021.
846 funds tracked by Wall St. Rank held Natera as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.